|
|
News Breaks | | | | February 20, 2013 | | 05:28 EDT |  | CRTX | Cornerstone Therapeutics receives take-private proposal of $6.40-$6.70 per share
Cornerstone Therapeutics announced that its board has received a letter from Chiesi Farmaceutici SpA. In that letter Chiesi, which owns approximately 60% of the outstanding shares of the company's common stock, made a proposal, subject to certain conditions, to acquire the shares of the company's common stock that it does not already own for a cash purchase price of between $6.40-$6.70 per share. The company cautions its stockholders and others considering trading in its common stock that no decisions have been made by the board with respect to Chiesi's proposal. There can be no assurance that any agreement will result from the proposal submitted by Chiesi or that any transaction based on Chiesi's proposal will be consummated. | |
|
News For CRTX From The Last 14 Days Check below for free stories on CRTX the last two weeks. |
|
|
| May 9, 2013 | | 07:48 EDT |  | CRTX | Cornerstone Therapeutics reports Q1 EPS 24c, one estimate 13c
Reports Q revenue $383M, one estimate $35.43M. | | | 06:47 EDT | | CRTX | Cornerstone Therapeutics acquires exclusive U.S. marketing rights to Pertzye
 Subscribe for More Information | |
|
|
|
|
|
|
